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Summary.-An attempt has been made to develop tritiated derivatives of Synkavit
(menadiol sodium diphosphate, MNDP) of high specific activity as a radioactive
drug.
This paper summarizes the preliminary biological and physical studies, with
emphasis on approximate radiation dosimetry and the necessary preliminary
testing, and then gives an account of the clinical investigations and the trials carried
out so far, which correspond essentially to Phases I and II trials for a chemothera-
peutic agent.
In all, 214 patients with different sites and types of advanced and recurrent,
inoperable, histologically verified malignant tumours including reticuloses have
been treated with doses of at least 1 Ci of the various preparations. Among the 203
evaluable treated cases, some form of response was observed in23 out of 151 (15-2%)
receiving the drug by intravenous injections and 13 out of52(25%) after intra-arterial
injections. For the sites and types of malignant diseases which showed responses
after either intravenous or intra-arterial administration among the 55 patients
surviving at least 3 months after the first injection, some form of response was
observed in 32 but only 5 of these showed either a " complete " or a " partial"
response.
It is concluded that further investigation is desirable. It is suggested that
clinical trials with randomization should be carried out for inoperable cases of
carcinoma of the colon and of the pancreas.
As A METHOD of improving the treat-
ment ofpatients with cancer, I thought it
was important to try to develop radio-
active drugs, i.e., compounds which are
concentrated selectively in the viable
malignant cells of tumours and carry
incorporated radioactive atoms in suffi-
ciently high specific activity to the right
place, in order to produce the radiothera-
peutic effect in situ, and without signifi-
cant damage to normal tissues. The
present work arose from studies of chemi-
cal radiosensitizers, which started in 1946
with Synkavit (Roche Products Ltd,
menadiol sodium diphosphate, MNDP).
We noticed that a few minutes after
intravenous injection of doses of 100-150
mg of MNDP some patients experienced
sensations or even local pain in the region
of the tumour. Following up this un-
expected finding, investigations showed
that MNDP, or a major metabolite of it,
concentrated to some extent selectively
in the malignant cells of some experi-
mental tumours in animals and certain
human tumours.
For therapeutic applications, we have
developed tritiated derivatives of MNDP
-abbreviated T-MNDP-incorporating
tritium, (3H) in very high specific activity.
This is the work of a team in Cambridge,
with the collaboration of the Radio-
chemical Centre, Amersham, Bucks., and
Roche Products Ltd, Welwyn Garden
City. It started in 1953 with the pre-
paration of. derivatives of MNDP andJ. S. MITCHELL
some related compounds, labelled with
14C, 82Br, 1311 and finally tritium, with
progressively increasing specific activity
(Maxwell, 1954, 1955; Marrian and Max-
well, 1956a, b; Marrian, 1957; Hor-
witz et al. (1959); Andrews et al., 1962;
Hodgson, 1968; Thomas, personal com-
munication, 1970). The various aspects
of this investigation and published work
on other radioactive drugs have been
reviewed (Mitchell, 1965, 1967, 1970,
1971a, b).
Relevant properties of tritiurn and
approximate clinical dosimetry
Tritium (3H) appears to be very suit-
able for incorporation into a radioactive
drug. Its radiobiological action is local-
ized in single cells or cell constituents.
It is a pure beta ray emitter with very
soft beta radiation which behaves biologic-
ally like a low LET radiation. The
beta particles are completely absorbed in
about 6 ,am in water and soft tissue of
unit density. The mean energy of the
beta particles is 5 73 ± 0 03 keV and the
corresponding range in unit density tissue
is approximately 0 9 rim. The radio-
active half-life is 12-4 years but almost
invariably the values of the biological
half-life (BHL) observed for human tissues
and tumours with the radioactive drugs
T-MNDP have been very much less,
often between 7 and 14 days for the main
half-life,though sometimesless, andinsone
cases greater for tumour than for normal
tissues (Chipperfield, 1967a). Values of
the main half-life found for carcinoma of
the rectum were 9 and 13 days; a value
of 3-4 days was observed in a case of
squamous carcinoma of the skin.
It is useful to introduce the concept
of the Differential Absorption Ratio
(DAR) defined as the ratio of the specific
activity ofthe tumour orrelevant normal
tissue to the mean specific activity of
the body as a whole. An important step
in the investigation of the individual
patient is the measurement of the specific
activity of tumour tissue, and also at
least one normal tissue, ifpossible. There
are, of course, some cases where it is not
practicable to carry out such procedures.
The most important quantitative rela-
tionship concerning the dosimetry is that
for uniformly distributed tritium at a
stationary concentration, 1 mCi per g of
tissue delivers a dose rate of 293 rad per
day (24 h).
As a first approximation, calculations
of radiation dose based on the assumption
of uniform distribution of the tritium in
normal tissues and tumours have proved
useful.
Assuming uniform distribution
throughout the body, 1 Ci of tritium
administered in a single injection to a
70 kg patient delivers a dose of 18-1 rad
for a BHL of 3 days, 36-2 rad for BHL
6 days, 54-4 rad for BHL 9 days, 72-5 rad
for BHL 12 days and 78-5 rad for BHL
13 days (Mitchell et al., 1963). The
approximate values of the equivalent
single doses, ifthe radiation were delivered
at a high dose rate, would be for the
different values of BHL, about 8, 14, 21,
27 and 29 rad respectively.
For most of the patients treated by
intravenous T-MNDP, repeated injections
have been given at intervals, often of 3
or 4 days, which in general are consider-
ably less than the BHL in the tumour but
are comparable with the BHL in the body
as a whole, as shown by excretion studies.
The approximate values of the doses
delivered to normal tissues and tumours
have been calculated, usually by means
of a two-exponential model, with corres-
ponding values of a short initial half-life
and a longer main half-life (Chipperfield,
1967a). It was found that in most cases
a power law gave a good or even better
fit for the dependence of specific activity
upon time but with this method calculation
of the dose delivered was more difficult
(White, 1973).
For doses calculated on the assump-
tion of a uniform distribution of the
tritium of T-MNDP in normal tissues and
tumours, it appears that in most cases
the clinical results are not inconsistent
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with experience of external radiotherapy,
if the further assrumption is made that the
RBE has the value of 15 in relation to
60Co gamma radiation. Such a value is
probably not inconsistent with previous
experimental findings (see e.g., Hall,
Oliver and Bedford, 1967, and our own
EM-autoradiographic studies, noting also
the work of Cleaver, 1971.).
However, the basis for these calcula-
tions can only be regarded as a crude first
approximation. In general, in addition
to macroscopic inhomogeneity there is
inhomogeneity of the microscopic distri-
bution of the tritium, which has been
studied by morphometry and by auto-
radiography including EM-autoradio-
graphy, in addition to measurements of
the specific activity of the tritium in
macroscopic specimens. With regard to
the human tumours studied (Chipperfield,
1967a), the initial uptake observed in
biopsy and surgical specimens taken 30
min after intravenous or intra-arterial
injection was highest in cases of carcinoma
ofthe gastrointestinal tract, with values of
22*1 ± 8-4 1Cli per g wet weight per Ci
injected for TRK 219 and 27*4 i 2X2 ,uCi
per g per Ci injected for TRA 119. In
some of these tumours and their metas-
tases there was abundant stroma which
showed low uptake, so that the mean
specific activity of the tumour cells may
be considerably higher than the average
value for the macroscopic specimen,
e.g., in one case by a factor of 6 3. There
is often wide variation among the tumour
cells and in different parts of the tumour.
Taking into account this distribution of
activity, it is possible to calculate an
approximate value of the nmean tumour
cell dose, but difficult to estimate the
minimum tumour cell dose, even though
the uptake is limited to viable tumour
cells. In a typical example of carcinoma
of the colon, the specific activity of the
gross specimen may be 20 ,uCi per g per
Ci injected, so that allowing for stroma
and necrotic areas by means of a factor
of 3*5, the mean specific activity of the
tumour cells would be 70 /tCi per g per Ci
28
and for a single dose of 10 Ci injected
0 70 mCi per g; the corresponding initial
mean tumour cell dose would be 205 rad
per 24 h. For a typical value of the
biological half-life of 10 days and mean
life 14 4 days, the total mean cell dose
delivered would be 2950, say of the order
of 3000 rad. Assuming a value of the
RBE of 1P5, the total mean tumour cell
dose would be equivalent biologically to
about 4500 rad of y radiation delivered
continuously over about 14 days.
Examples of calculations for the repeated
small doses generally used in the treatment
of individual patients will be discussed in
considering the results.
From the point of view of detailed
dosimetry, as a further extension of the
ordinary (light microscopic) autoradio-
graphy (Mitchell et al., 1963) quantitative
EM-autoradiographic studies have been
carried out on tumour cells in sections
from patients treated with T-MNDP.
Significant concentration, often by factors
of 3-5, was found in the nucleoli and
nucleolus associated chromatin, mainly
in the mid and late S and early G2
phases.
It is to be noted that the introduction
of tritium as a hydrogen isotope into an
organic molecule such as MNDP causes no
change in its chemical structure or
pharmacological properties. Almost cer-
tainly there is no significant isotope effect.
Moreover, the properties of tritium and
of T-MNDP and its metabolism are such
that the handling of these preparations
presents no serious difficulties in thera-
peutic applications. The health and
safety precautions described (Mitchell,
1965) have been extended to the treatment
of outpatients with unit amounts of up to
5 Ci but usually not more than 3 Ci bv
intravenous injection.
MATERIALS AND METHODS
Preparations ofT-MJIVDP used.-The first
preparations of T-MINDP, called TI, were
made by the Wilzbach procedure but some of
these appeared to contain tritiated water asJ. S. MITCHELL
an impurity, which was toxic to the bone
marrow. The specific activity of TI cor-
responded to approximately one atom of
tritium per molecule of MNDP. These
preparations were used from 4 February 1959
to 17 August 1960 for the treatment of cases
Nos. 1-27.
Since September 1960 all the preparations
of T-MNDP have been made by chemical
synthesis, the tritium being incorporated in
firmly bound positions by means of catalytic
dehydrogenation ofthe corresponding halogen
derivatives (Andrews et al., 1962). We
described these preparations following the
catalogue of the Radiochemical Centre:
TRA 72, containing theoretically one atom
of tritium in the 6-position, had maximum
specific activity 29-1 Ci/mmol, corresponding
to 1 Ci in 14-64 mg of compound, and was
used from 21 September 1960 to 5 May 1961
for the treatment of cases Nos. 28-48. TRA
119 contained up to 3 atoms of tritium per
molecule in the 5, 6 and 7 positions, with
maximum specific activity 87-3 Ci/mmol,
corresponding to 1 Ci in 4-88 mg, and was
used from 7 March 1962 to 12 December 1963
in the treatment of cases Nos. 49-99. A
more reliable preparation was the next one,
TRK 219, wrhich contained 2 tritium atoms per
molecule in the 6 and 7 positions with
maximum specific activity 58-2 Ci/mmol,
corresponding to 1 Ci in 7 32 mg, and was
used from 24 September 1964 to 19 June 1970
for cases Nos. 100-224. Attempts were
then made again to prepare the compound
wNith 4 tritium atoms per molecule in the 5, 6,
7 and 8 positions (Hodgson, 1968; Thomas,
personal communication, 1970). This pre-
paration, TRK 397, varied in specific activity
among 8 batches from 83 Ci/mmol up to
105 5 Ci/mmol, corresponding to 3-63 tritium
atoms per molecule and 4-03 mg per Ci, and
was used from 18 August 1970 to 12 Sep-
tember 1972 for cases Nos. 225-260. The
preparation, TRQ 347, of specific activity
70 Ci/mmol was used from 6 February 1973
to 20 March 1973 for cases Nos. 261, 262 and
264. The preparation, TRQ 368, of specific
activity 85 Ci/mmol was used from 1 May
1973 to 28 June 1973 for cases Nos. 263, 265
and 266. The solutions are sterilized by
filtration into rubber capped bottles and
frozen; the bottles of solution are stored in
the gases above liquid nitrogen at about
-196°C in a commercial liquid nitrogen
refrigerator " (Union Carbide Ltd). Storage
at this temperature reduces the rate of
decomposition by a factor of at least 5
(Evans, 1966).
With these radioactive drugs, one needs
a high degree of radiopharmaceutical purity,
as well as of radiochemical purity. Even
nouw, the individual batches may differ in
biological properties. For this reason every
batch of T-MNDP is tested routinely on
tissue cultures with autoradiography to be
certain of a high degree of selective uptake
in cells of a human tumour strain, Hep/2
(derived from a nasopharyngeal carcinoma)
with negligible uptake into cells of normal
origin, for which we now use mouse L cells.
In earlier stages of the testing, other cells
were included, viz., HeLa cells and normal
cells of human amniotic epithelium and
embryonic skin, and lung epithelium, as well
as monkey kidney cells (Simon-Reuss, 1961;
Dendy, 1969; Morley and Dendy, 1973). A
bad " batch shows uptake into the cells of
normal origin. Quantitatively, ' good "
batches show from 30 up to even 100 times
the uptake into the tumour cells compared
with that in the normal cells. These tests
also provide a check for sterility. In addi-
tion, every batch has been tested to exclude
acute toxicity-which has never been
observed afterintravenous injection in rabbits
in doses corresponding to 11 Ci and 22 Ci/70
kg body weight. These rabbits have been
kept for the rest of their life span for studies
of possible late radiation effects.
Pre-clinical testing.-In this investigation,
using the preparations of T-MNDP of very
high specific activity, the chemical toxicity
of MNDP is negligible (Mitchell, 1948, 1949).
In addition to the tissue culture studies,
many experiments have been carried out on
mice, rats and rabbits; these have been
continued throughout the years and included
haematological studies on the rabbits. Di
Vita (1964, personal communication) showed
that in mice for a single intraperitoneal
injection of TRA 72, the LD 50/30 days was
about 20 mCi/g body weight, but only 1 1
mCi/g for tritiated water, for which there is
essentially uniform distribution of the radio-
activity: a value of about 1 mCi/g had also
been found for tritiated water by Brues,
Stroud and Rietz (1952). The results of our
distribution studies with T-MNDP in rats
wvith the Walker carcinosarcoma 256 were
confirmed for mice with spontaneous mam-
maryadenocarcinoma by Ganatraet al. (1969).
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Information of great value from the point
of viewr ofthe clinical applications in man wAas
obtained in studies of the treatment of
spontaneous malignant tumours and leukae-
mias in cats and dogs by our veterinary
colleague, Dr I. A. Silver (Silver et al., 1962).
For example, 5 out of 7 cases of carcinoma of
the tongue and palate in cats responded
favourably to initra-arterial injection of
quite small doses of T-MNDP and 2 of these
lived longer than 2 years: tumours of these
sites did not respond satisfactorily to external
radiotherapy with 220 kVp x-rays. In
addition, in long-term studies in 4 normal
puppies aged 3 months (2 male and 2 female)
injected wAith single doses of TRK 219
equivalent to 22 Ci/70 kg body -weight, there
was no effect on bone growth or epiphyseal
closure. No abnormalities of any sort could
be detected in any of the 4 in life or at post-
mortem examination at 1, 2, 3 and 4 years
respectively. The 2 longest surviving pup-
pies, one male and one female, wAere mated
w,ith other dogs and fathered or produced
normal litters. Subsequently they ere
mated together and also produced a normal
litter. Measurements of the radioactivity of
tissues taken at autopsy from other dogs
showed relatively high activities in the eye
(lens and retina), kidney, intestine and
pancreas within a few hours of treatment.
Nine months after treatment one case still
had detectable activity in marrowx- and
retina. No changes in the fundus of the eye
or defects of vision wA-ere observed (Professor
1. A. Silver, personal communication, 1970).
Clinical trials a)?d relevaiat clinical
investigations
The design and analysis of the clinical
investigations of T-MNDP have followed
the general plan wTidely used for the examina-
tion of new chemotherapeutic agents (Brule
et al., 1973). However, the problems
involved wAere not as fully understood when
these trials wN-ere started in February 1959
as at present and, moreover, there are essen-
tial differences betwTeen a radioactive drug
such as T-MNDP and most chemotlhera-
peutic agents. There is no serious problem
of chemical toxicity because of the high
specific activity of the preparations of
T-MiNDP used. There wN-as already a sub-
stantial body of knowledge concerning the
effects and hazards of internally administered
radioactive isotopes, and very considerable
clinical experience of the uses of 1311 and 32p
in inorganic form in therapy. The value and
limitations of approximate dosimetry for
these two isotopes had been emphasized in
many investigations, including our own
(Phillips, 1954, 1957; Phillips and Saunders,
1957; Phillips, Haybittle and Newberry,
1960; Mitchell, 1955, 1971a, b). With
T-MNDP, the estimated radiation doses
proved to be a reliable starting point as a
first approximation, which enabled us to
make rapid progress. Partly because of
this, and also because no other basis would
have been acceptable, wre set out to include
assessment of anti-tumnour action in the
Exploratory Phase, corresponding to Phase I,
of our trials. Further, the investigations
which can be regarded as within the scope of
clinical pharmacology as applied to a radio-
active drug have continued throughout most
ofPhase II; also the quality ofthe radioactive
drug has improved steadily over the years.
In Phase 1, we started the treatment of
patients with advanced or refractory
tumours" using intra-arterial (i.a.) injection,
mainly with the Seldinger technique as
developed by Dr D. McC. Gregg (1958), and
then used intravenous (i.v.) injections in
patients withgeneralized metastases " (Hor-
wNitzet al., 1959). WenotedthatGehan (1961)
had shown that if a drug wAere effective in
20% of patients, or more, there wNould be a
950 chance of one or more successes in 14
consecutive cases. Wre found 5 responses
which were estimated on the modest basis
of reduction in size of the tumour, or of part
ofthe tumour in the first 14 cases. Accord-
ingly, w!e felt wre must continue the investiga-
tion and wre were encouraged by the relief of
pain we observed in 5 ofthese patients.
From the beginning we started relevant
investigations and first obtained evidence of
uptake of T-MNDP in tumours after i.a.
injection. Detailed studies oftritium uptake
and distribution, half-lives and radiation
doses, and excretion and metabolism have
continued (Horwitz et al., 1959; Marrian,
Marshall and Mitchell, 1961: Marrian et al.,
1965; Chipperfield, 1967a, b; see also White,
1973). Summarizing our findings, including
those on autopsies, after a single injection of
10 Ci of T-MNDP/70 kg body weight, the
total doses, wNith standard deviation, received
by normal tissues were estimated as follows:
kidney 222 ± 78 rad, testis 180 ± 29 rad,J. S. MITCHELL
bone marrow 83 ± 65 rad, liver 145 ± 78
rad, brain (long-lived component only)
137 r 46 rad, skeletal muscle 54 f 26 rad
and small intestine 93 = 29 rad.
Phase 11, the main part of the trial so far,
which is concei-ned with screening for clinical
activity, has now been completed after the
treatment of a further 200 cases. We
selected the correct range of dosage from the
beginning, so that the patients in both
Phases I and 11 can be evaluated as a single
gr-oup. All patients have been re-assessed in
terms of present criteria. The selection of
patients for treatment by means of T-MNDP
wvas always discussed with colleagues. I
examined all the patients myself, often
throughout the treatment and at least at
some stage of the treatment and follow-up;
in most cases, I gave the intravenous injec-
tions myself.
From 4 February 1959 to 13 July 1973 we
have treated, wvith doses of at least 1 Ci ofthe
various preparations of T-MNDP, a total of
214 patients wvith different types of advanced
and recurrent, inoperable, histologically veri-
fied malignant tumnours and reticuloses.
These tritiated drugs wAere used only when all
other therapeutic measures surgery, radio-
therapy, chemotherapy and hormone therapy
had failed or wvere definitely contra-
indicated. Many of the patients were very
ill and in poor' general condition.
Assess)nent of the results of treatment wvith
T'-MNDP
The following criteria wvere used for
assessment:
Curative. Well and free firom clinical
evidence of disease at 5 years or more after
first treatment with the radioactive drug,
noting whether alive or dead.
Palliative.-Survival after first treatment
with the radioactive drug, and
Clinical responses (Hill and Larsen, 1972;
Gerner and Moore, 1973) were defined as
follows: C.R. cornplete response. All
ineasurable signs and all symptoms oftumour
disappear; P.R.-partial response. At least
a 5000 decrease in the maximum crQss-
sectional area of the tumour without simul-
taneous progression of disease elsewhere:
Iic.R. incomplete response (extension of
the term ' lesser response' as defined by
Gerner and Moore, 1973) including: (a)
reduiction of the size of the tumour with less
than a 5000 decrease in the maximum
cross-sectional area, or (b) more than a 500o
decrease in the maximum cross-sectional
area of the tumour or of parts of the tumour,
wzTith simultaneous progression of the disease
elsewhere, or (c) significant improvement of
general condition and increase in performance
status (Karnofsky et al., 1951) or (d) useful
relief of pain, if possible assessed in terms of
reduction of the amounts of analgesic drugs
required, or (e) relief of intractable pruritus,
or more than one of these criteria.
Responses were required to persist for at
least 4 weeks.
None. No significant clinical response.
This includes: no change or stationary
disease, and progression, defined as a measur-
able increase in the maximum cross-sectional
area of the tumour greater than 250%, or
appearance of new lesions, or definite worsen-
ing of the patient's general condition.
N.E. Non-evaluable treatments were
studied, and classified as follows: Not
evaluable because treatment was initiated
prophylactically for poor prognosis as adju-
vant therapy following, or in association
with, radiation therapy or surgery, including
potentially curative measures, or not curable
by standard means, but no lesions were
evaluable for measurement. Included were
patients who were treated with radiation
therapy and chemotherapy simultaneously
or previously and in this case died within
1 month of the complications of the previous
treatment.
RESULTS
The results of treatment of the 162
patients with the various preparations
of T-MNDP administered by intravenous
injection are sunmmarized in Table I. Of
these patients, 151 were evaluable. The
numbers of patients showing the different
types of clinical response are listed and
the footnotes give additional information.
Table I includes the total dose in Ci
received by patients showing some clinical
response. Except for single doses of up
to 4 Ci, these total doses were delivered
in a series of repeated injections, often
2-3 times weekly, each single injection
usually not exceeding 3 Ci. Mention
must be made of 2 patients (Cases Nos.
119 and 157) who received exceptionally
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TABLE I. Summary of Ressults of Treatment with Tritiated MNDP Administered
by Intravenous Injection
Histologically verified cases
Site and type
of tumotur p
Ca stomach
Ca colon
Ca recttum
Ca pancreas
Ca breast(h)
Ca ovary
Malignant melanoma
Ca gall bladder and
and bile ducts
Sarcoma, various
types
Ca bronchus
Hodgkin's disease
Myelomatiosis
Other reticuloses aiic
related malignancies
MIalignant tumours of
other sites, various
types, mainly
carcinoma
Totals
Total
no. of
atients
No.
not
evalutable
No. of
patients
evaluable C.R.
Clinical respjonses
among all patients
P.R. Inc.R. None
Comments an1(l
total (lose in Ci
receive(l by
respond(ers
19 2 17 0 O ( 17 No responses
33 2 31 0 1(a) 3 27 11-2, 11-3(a), 19-6
ain(i 58 Ci
13 3 1 5 7 5 7, S ;, aI1(I 1 O0
ci
7 (0 7 0 2 1 4 134 andl 22 Ciw ith
P.R.; 9 (0 Ci with
Inc.R.
8 0) 8 0 0 2 (6 4andO 10-I Ci
6 1 5 0 0 2 3 18-5annd34Ci
16 (0 16 0 0 3 13 25, 37and 5S8Ci
0} 4 0 0
12
10
3
2
0
12
8
3
0 0
0 0
1(c) 0
3 0 3 0 0
6 0
12
162 11
3 45 Ci
12 No responises
8 No responses
l0 10 Ci with
C.R.(e): 7.) an(i
19 8 Ci with Inc.R.
2 149 Ci
0 0 l (d) 5 3-1 Ci(d)
21
151
0) 0} 0 21)I
1 3 1l) 128
No responses
(a) Carcinoma became operable and was treated surgically 8 inonths after first inijection; patient alive
an(l well at 2 years after resection.
(b) Female patients; in addition one male patient show%ed no response.
(c) C.R. possibly curative: patient alive and well after 8 years with no evi(delnce of disease.
(d) Chronic lymphatic leukaemia.
high total doses of 58 Ci given in 11 injec-
tions in 81 days and 19 injections in 154
days respectively; these patients will be
discussed later.
No responses were observed in 17
evaluable patients in the trial with carci-
noma of the stomach, 8 with carcinoma
of the bronchus or the 12 with various
types of sarcoma after intravenous injec-
tions of T-MNDP. Table II summarizes
the results for the remaining 88 evaluable
patients with sites and types of malignant
diseases which showed some responses
after treatment by means of intravenous
injections. To overcome the problem
that many of the patients were very ill
and in poor general condition, in Table II
separate consideration is given to the
ntimber and clinical responses of patients
surviving 3 months or more after the first
injection of the radioactive drug. In
addition, the number of patients showing
each type of incomplete response (Inc.R.)
is shown.
Table I shows that among the 151
evaluable cases treated with intravenous
injections, 23 (152%0) showed some form
of response, i.e., C.R. (complete response),
P.R. (partial response) and Inc.R. (incom-
plete responses). Table II shows that
for the sites and types of malignant
diseases which showed responses, some
form of response was observed in 23 of
the 88 patients, i.e., 26l1%. Among the
42 patients surviving at least 3 months
after the first intravenous injection there
were, 1 C.R. possibly with a curative
result in Hodgkin's disease, with recurrent380 J. S. MITCHELL
TABLE II.-Summary of Result8 of Treatment with Tritiated MNDP Admini8tered
by Intravenous Injection
Evaluable Histologically Verified Cases for Sites and Types of Malignant Diseases which Show Responses
No. and clinical responses No. of
of evaluable patients patients
surviving 3 months or more showing
Clinical responses among after first injection of each type
No. of all evaluable patients radioactive drug of Inc.R.
Site and type evaluable , A_ _ A , _ _ _ _ _
of tumour patients C.R. P.R. Inc.R. None No. C.R. P.R. Inc.R. None a b c d e
Ca colon 31 0 1(a) 3 27 10 0 1(a) 3 6 1 0 1 1 0
Ca rectum 10 0 0 3 7 9 0 0 3 6 0 0 1 2 0
Ca pancreas 7 0 2 1 4 5 0 2 1 2 0 0 0 1 0
Ca breast(b) 8 0 0 2 6 4 0 0 2 2 0 0 1 1 0
Ca ovary 5 0 0 2 3 3 0 0 2 1 0 0 2 0 0
NMalignant melanoma 16 0 0 3 13 5 0 0 2 3 0 3 0 0 0
Ca gall bladder and bile
ducts
Hodgkin's disease
Myelomatosis
Chronic lymphatic
leukaemia
Totals
4
3
3
0 0 1
1(C) 0 2
0 0 1
3
0
2
1
3
1
0 0
1(c) 0
0 0
1
2
1
0
0
0
1 0000
1 0 0 0 1
O O 0 1 0
1 0 0 1 0 1 0 0 1 0 0 1 0 0 0
88 1 3 19 65 42 1 3 18 20 3 4 5 6 1
(a) Carcinoma became operable and was treated surgically 8 months after first injection; patient alive
and well 2 years after resection.
(b) Female patients.
(e) C.R. Possibly curative; patient alive and well after 8 years with no evidence of disease.
cervical nodes after previous radiotherapy,
3 P.R., one of which was a case of carci-
noma of the colon made operable and the
other 2 of carcinoma of the pancreas, and
18 Inc.R., some of which were striking.
For intra-arterial administration, all
52 patients treated with doses of 1 Ci or
more were evaluable. Table III sum-
marizes the results and includes the total
doses received by those patients showing
some clinical response. Up to 3 intra-
arterial injections were given in a number
of these patients; the maximum dose
given at one injection was 12 Ci. The
numbers of patients in almost all the
groups treated by intra-arterial injection
are small; no responses were observed
for carcinoma of the colon, rectum,
ovary, bronchus or kidney and renal
pelvis. Among 13 cases of inoperable
cerebral glioma, there were no responses
after intra-arterial therapy. In addi-
tion, in one case, No. 102, a man of 31,
3.8 Ci was injected into a cyst in an
inoperable cerebral glioblastoma multi-
forme recurrent after previous external
radiotherapy; the patient improved in
general condition for at least 2 months
[Inc.R.(C) (which could, of course, have
been related to the aspiration)] and died
at 11 months after the intracystic injec-
tion.
Table III shows that among the 52
patients treated by intra-arterial injec-
tion, 13 (25%) had some form ofresponse.
Table IV gives further details of the
results of intra-arterial treatment with
T-MNDP for the 18 patients with malig-
nant diseases of sites and types which
showed some responses. Among the 13
of these patients surviving at least 3
months after the first intra-arterial injec-
tion, there were 1 P.R., in a case of
multiple metastases of malignant nela-
noma on the leg, with freedom from any
evidence of disease for 3 years 4 months,
and 9 Inc.R.
For all the evaluable patients in the
trial treated by both the intravenous and
intra-arterial routes, there was some form
of response in 36 out of 203 (17.7%);
however, for C.R. + P.R. there were only
6 responses out of 203 (approximately
3%). For the patients with sites and
types oftumours which showed responses,
some form of response was observed in 36
C C%I
t
I
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TABLE III.-Summary of Results ofTreatment with Tritiated MNDP Administered
by Intra-arterial Injection
Histologically Verified Cases, all Evaluable
Clinical responses
Total among all patients Comments and
LI', i 1- ,,I , .1 Site and type
of tumour
Ca jejunum
Ca colon
Ca rectum
Tumours of kidney
Ca ovary
Seminoma testis
Malignant melanoma
Cerebral tumours
Sarcoma, upper end of
femur
Ca bronchus
Ca cervix
Ca vagina
Ca antrum
Ca parotid
Malignant tumours of
other sites, various types
Totals
np
pat
O. of total dose in Ci
tients C.R. P.R. Inc.R. None received by responders
1 0 0 1 0 3 Ci
3 0 0 1 2 4-2 Ci
5 0 0 0 5 No responses
2 0 0 0 2 No responses
3 0 0 0 3 No responses
1 0 1 0 0 3 Ci
4 0 1 2 1 16 Ci with P.R.; 2 and 25
Ci with Inc.R.
13(a) 0 0 0 13 No responses
2(b)
4
4
1
1
0
0
0
0
0
0
0
0
0
0
0
0
2
0
2
1
1
1
0
4
2
0
0
0
7 0 0 0 7
52 0 2 11 39
6 and 11 Ci
No responses
3-0 and 12-2 Ci
12 Ci
23-7 Ci
2-8 Ci
No responses
(a) In addition, one case with Inc.R. after injection of 3 - 8 Ci into cyst.
(b) One fibrosarcoma and one chondrosarcoma.
TABLE IV.-Summary of Results of Treatment with Tritiated
by Intra-arterial Injection
MNDP Administered
Histologically Verified Cases, all Evaluable, for Sites and Types ofMalignant Diseases which Show Responses
No. and clinical responses No. of
of patients surviving 3 months patients
No. of Clinical responses or more after first injection showing
patients, among all patients of radioactive drug eachtype
Site and type all A,A_ , ofInc. R.
of tumour evaluable C.R. P.R. Inc.R. None No. C.R. P.R. Inc.R. None a b c d
Ca jejunum 1 0 0 1 0 0 0 0 0 0 0 0 0 1
Ca colon 3 0 0 1 2 3 0 0 1 2 1 0 0 0
Seminoma testis 1 0 1 0 0 0 0 0 0 0 0 0 0 0
Malignant melanoma 4 0 1 2 1 3 0 1 2 0 0 1 0 1
Sarcoma, upper end of
femur
Ca cervix
Ca vagina
Ca antrum
Ca parotid
Totals
2
4
1
1
1
18
0 0 2 0 2 0
0 0 2 2 2 0
0 0 1 0 1 0
0 0 1 0 1 0
0 0 1 0 1 0
0 2 11 5 13 0
out of 106 (34.0%); for C.R. + P.R. there
were 6 among the 106 patients. Among
the 55 of these patients surviving at least
3 months after the first injection, there
was some form of response in 32 (58.2%);
however, for C.R. + P.R. there were 5
out of the 55.
0
0
0
0
0
1
2
1
1
1
1
9
0
1
0
0
0
3
200
100
100
1 00
000
610
0
1
0
U
1
4
Relevant details about some selected
patients
Case No. 233 (Addenbrooke's Hospital No.
361274)
P.R. Female, 74 years. Carcinoma of
descending colon high up near splenic
flexure, inoperable, solidly adherent to the
I-J. S. MITCHELL
left kidney and other posterior abdominal
wall structures. Moderately well-differen-
tiated adenocarcinoma. On phenobar-
bitone for some years. Striking uptake wNas
observed in scan with 6-1311-iodo-MNDP.
'I'he total dose of 11-3 Ci of TRK 397 was
given in 8 intravenous injections in 25 days.
Body weight 57 kg. For 70 kg body weight,
this is equivalent to 8 injections each 1P74 Ci,
with total 13-9, say 14 Ci. Assuming a
biological half-life (BHL) of 9 days and
DAR = 5 for the tumour cells, the total
mean dose delivered would be 3780 rad.
With RBE _ 1-5, the equivalent total mean
dose of _iCo gamma radiation to the tumour
cells is about 5700 rad delivered in a time
probably equivalent to an overall time of
38 days, corresponding to the time between
the first and last injections plus the assumed
biological mean life of 13 days. There were
no serious blood count changes. The mini-
mum values reached were wbc 3000 and
platelets 129,000/cm3 at 29 days after the
last injection.
A useful clinical response was obtained.
Trhe palpable mass disappeared from 2 to 7
moniths after the start of the injections but
greN again slowly. The condition was then
regarded as operable and was treated surgic-
ally at 8 months after the first injection, with
resection of splenic flexure with left kid-
ney". The patient was alive and well 2
years after the resection.
Ca,-se No. 209 (Addenbrooke's Hospital No.
83494)
P.R. Male, 52 years. Carcinoma of tail of
pancreas wAith metastases in liver inoperable
at laparotomy. Undifferentiated carcinoma
wNith occasional acini, some containing mucus.
Striking uptake was observed in scans with
6-1311-iodo-MNDP. From measurements on
a phantom model, the value of the macro-
scopic average DAR for uptake of 6-131I1
iodo-MNDP into the primary tumour mass
was found to be 6-8 (say 7) (Mitchell, 1971a,
p. 66 and Fig. 4). The total dose of 13-6 Ci
of TRK 219 was given in 6 intravenous
injections in 15 days. Body wreight 54 kg.
For 70 kg, this would be equivalent to 6
injections each of 2-93 Ci, w\ith total 17-6 Ci.
Sodium citrate mixture was given orally
during the treatment to try to increase the
u]ptake into the tumour. Assuming BHL 6
days and DAR = 7 for the tumour, the total
mean dose delivered would be 4450 rad.
With RBE = 1-5, the equivalent total mean
dose would be about 6700 rad, delivered
in an effective time of about 24 days. There
were no serious blood count changes. The
minimum values reached were wbc 2900 and
platelets 195,000/Cm3 at 23 days after the
last injection.
The abdominal mass below the left
costal margin became only just palpable or
not palpable for at least 4 weeks and then
slowly enlarged. At 2 months after the end
of the first course of injections, a second
course was given to a total dose of 8-4 Ci
in 3 injections in 7 days. There was only
slight improvement in general condition, with
a little reduction in size of the mass. The
patient died 4 months 15 days after the start
of the first course of injections.
Case .No. 266 (Addenbrooke's Hospital No.
339607)
P.R. Female, 23 years. Proven metastases
liver and coeliae axis lymph nodes, almost in
certainly primary carcinoma in body of
pancreas-inoperable at laparotomy; also
hypercaleaemia with no radiological evidence
of metastases in bones. Poorly differen-
tiated adenocarcinoma. The total dose of
15-4 Ci was given in 7 intravenous injections
in 16 days. Body weight 41-5 kg. For 70
kg, this would be equivalent to 7 injections
each of 3-71 Ci, with total 26 Ci. During the
injections, the patient w\as treated with
prednisone 30 mg daily and also chloroquine
sulphate 200 mg tablets twice daily (as a
DNA repair inhibitor; Mitchell, 1973); this
was continued for 4 weeks after the injec-
tions. Assuming BHL 6 days and
DAR = 5 in the tumour cells, the total mean
dose delivered would be 4690 rad. With
RBE= 1-5 the equivalent total mean dose
would be about 7000 rad, delivered in an
effective time of about 25 days. There were
no serious blood count changes. The mini-
mum values reached wNere wbc 3500 and
platelets 103,000/cm3 at 27 days after the
last injection; the neutrophils showed toxic
granulations.
There was a steady reduction in the size
of the liver for at least 3 months and striking
improvement of the general condition for at
least 2 months. Then she deteriorated very
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slowly but finally died after about a week's
illness with bronchopneumonia and pains
in the back and legs, possibly due to spinal
metastases, at 157 days after the first
injection.
Case No. 13 (Addenbrooke's Hospital No.
162632)
P.R. Male, 60 years. Massive recurrence
in abdomen and pulmonary metastases from
seminoma arising in undeseended testicle,
after surgery and large field radiotherapy,
which resulted in a leueopenia reaching
1500 wbe/Cm3, and 2 blood transfusionls. A
single intra-aortic injection of 3 Ci of TI was
given. The catheter was inserted intra-
arterially by the Seldinger method, Nith the
tip in the aorta below the branch to the left
subelavian artery. Body weight 58 kg. The
abdominal mass shrank rapidly and became
only just palpable. The oedema of the legs
disappeared. The patient no longer needed
morphia for the pain and he could lie flat in
comfort. At 33 days after the injection rapid
deterioration occurred, almost certainly due
to a haemorrhage into tumour. The Hb
fell to 8-1 g/100 ml and rapidly over 14 days
the total wbc fell to 400 and the platelets
from 115,000 to 10,000/cIn3. A blood trans-
fusion was given but the patient died 9 days
later. Autopsy showed complete necrosis of
the para-aortic mass, hypoplastic sternal
marrow and sheets of seminoma cells in the
liver, lung parenchyma and lymph nodes
adjacent to the left bronchus.
Case No. 14,5 (Addenbrooke's Hospital No.
168033)
Inc.R.(c), Female, 57 years. Advanced
recurrent cai-cinoma of ovary after previous
incomplete surgery, radiotherapy and later
chemotlherapy with prednisone 15 mg daily
orally and chlorambucil 10 mg daily which
was tolerated for only 2 months. Mucinous
cystadenocarcinoma. Slhe was admitted to
hospital ' for terminal care " in very poor
general condition (performance status 20-
300o) with widespread metastases in the
bones of the skull and pelvis, bilateral
papilloedema, a subcutaneous mass over the
left scapula and miliary carcinomatosis of
the lungs, w%ith bilateral pleural effusions
containing malignant cells.
She was treated by a course ofintravenous
injections of TRK 219 to a total dose of
31-4 Ci in 10 injections in 34 days. Body
weight 45-8 kg. The sternal marrow showed
uptake in a group of cells regarded as tumour
cells. Prednisone 10 mg daily wAas continued.
(For body weight 70 kg, the total dose would
be 48 Ci). Assuming BHL 6 days and
DAR = 3, the total mean dose delivered
would be about 5200 rad. WAith RBE = 1 5,
the equivalent total mean dose would be
about 7800 rad delivered in effective time
about 43 days.
After being rather ill, though relieved by
aspiration of the pleural effusion and a blood
transfusion, she improved considerably in
general condition, the palpable tumour
masses became less tender and slightly
smaller and the papilloedema decreased.
She said that after the injections she felt like
she did after the previous external radio-
therapy.
The blood count shoNed serious changes
at about 44 days after the first injection with
minimum values Hb 7-3 g/100 ml, total
wbc 1200, with lymphocytes 516 and platelet
count 10,000/cm3; rapid recovery occurred
within 2 weeks after blood transfusions.
There was striking subjective improve-
ment with P.S. 80-90% for 10 weeks. She
acquired a new- flat and new furniture and
went away for a holiday. Then she deterior-
ated with increasing size of the tumour
masses but with an essentially normal blood
count. There was no response to a further
single intravenous dose of 2-6 Ci of TRK 219.
She died at 6 months 10 days after the first
injection. Autopsy showed carcinomatosis.
The bone marrow appeared normal, the
kidneys were congested and showed some
scarred glomeruli.
Case Vo. 81 (Addenbrooke's Hospital No.
174744)
Inc.R.(e), Female, 20 years. Hodgkin's
disease, probably of nodular sclerotic type,
afterpreviousradiotherapyandchemotherapy.
On prednisone 20 mg daily orally. Dramatic
relief of intractable pruritus about 4 h
after a single intravenous injection of 2-9 Ci
of TRA 119 in 21 mg of MNDP. Body
weight about 67 kg. A further injection
of 5 Ci was given 4 weeks later. There was
no return ofserious pruritus for the remaining
4 months of her life.J. S. MITCHELL
Comnplications
Haematological changes are the most
obvious problem. A white blood cell
count reduction to less than 2000 and/or
platelet reduction to less than 25,000/cm3
have been regarded as serious (Hill and
Larsen, 1972). In previous untreated
patients, doses of up to the equivalent of
a total of 26 Ci given in 7 intravenous
injections in 16 days/70 kg body weight
resulted in no serious changes in blood
count. The safety of a single injection
of 11 Ci/70 kg body weight was confirmed
for patients without serious bone marrow
damage at a relatively early stage of this
work (Mitchell et al., 1963). The toler-
ance of the bone marrow can be greatly
reduced by previous large field radio-
theiapy (see Case No. 13) and/or chemo-
therapy (see Case No. 115), and/or
extensive involvement by growth. The
maximum dose which could be given to a
previously untreated patient without risk
of serious bone marrow damage is prob-
ably about 45 Ci/70 kg body weight given
in 10-15 injections in about 34 days.
Mention must be made of 2 patients
who received exceptionally high total
doses in probably unwise attempts to
control advancing disease which had
previously shown some response. Case
No. 119, a man of 36 with advanced
recurrent carcinoma of the colon and
pulmonary metastases (body weight 66 kg)
received a first course with a total dose
of 40 Ci in 7 intravenous injections in 39
days; then after an interval of 31 days
received a further 18-2 Ci in 4 injections
in 11 days, but died 30 days later, the
autopsy showing carcinomatosis and a
hypoplastic bone marrow. Case No. 157,
a man of 23 with recurrent generalized
metastases ofmalignant melanoma, from a
primary melanoma on the lowerleg treated
surgically (body weight 66 kg), received a
total amount of 57-8 Ci in 19 intravenous
injections approximately weekly in 154
days; from the second injection onwards,
the intravenous injection was given in the
hyperbaric oxygen tank at 3 atmospheres
absolute pressure of oxygen, to try to
increase the selective uptake into the
tumour. At 12 weeks after the last
injection, the Hb fell to 4-75 g/100 ml, the
wbc to 2700 and the platelets to less than
10,000/cm3. There were retinal haemorr-
hages, though it is to be noted that
melanotic deposits were evident in each
macular area about 8 weeks later. How-
ever, after blood transfusion the blood
picture improved and the patient survived
a further 14 weeks.
A clinical problem which has arisen
is the occurrence of necrosis in tumour
masses within the body after treatment
with T-MNDP (see Case No. 13). This
can lead to toxic absorption and a
clinical picture similar to " crush syn-
drome "; this should probably be treated
surgically ifpossible. A striking example
was seen in a case (No. 125) of advanced
carcinoma of the gall bladder with pul-
monary metastases, treated with a striking
immediate response, to a total dose of
45-2 Ci given in 8 injections in 99 days
(body weight 48 kg). Toxic absorption
from extensive necrotic tumour was prob-
ably the main cause of death at 25 days
after the last injection; the autopsy
showed almost aplastic marrow but the
kidneys were undamaged.
In these trials there has never been
evidence ofrenal damage. It is important
to note that experience of the treatment
of carcinoma of the thyroid with large
doses ofradio-iodine, 1311, has shown that
there is no evidence of long-term damage
to the kidney (Pochin, 1969, personal
communication).
In one case (No. 52) of multiple
metastases of malignant melanoma on
the leg, intra-arterial therapy with TRA
119 reduced the tolerance of both skin
and underlying bone to small field local
radiotherapy; a normal dose of external
220 kVp x-rays resulted in a local radio-
necrosis, requiring surgical treatment and
skin grafting.
Nausea is a notvery common andnever
serious complication and has been experi-
enced by some patients even after intra-
venous injections of 2-3 Ci; it is con-
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trolled almost invariably by oral perphen-
azine (Fentazin) 4 mg tablets; usually
one tablet is taken about half an hour
before the injection and another 2 h
afterwards.
Three patients appeared to be made
worse by intravenous injections of
T-MNDP, one case (No. 97) with multiple
recurrent secondary skin nodules of malig-
nant melanoma, another (No. 68) also
with multiple metastases of malignant
melanoma and shortly afterwards develop-
ing cerebral metastases, and a case (No.
211) of advanced carcinoma of the colon
which obstructed after the intravenous
injection of 2-9 Ci, presumably due to
local oedema. Another patient (Case
No. 244) with an inoperable carcinoma of
the colon, which had previously perforated
and been treated surgically by palliative
sigmoid colectomy, experienced abdominal
pain even after single intravenous doses of
0 5 Ci of TRK 397; it was only possible to
give a total dose of 2-5 Ci.
After intra-arterial injection, one case
(No. 5) developed a femoral arterial myco-
tic aneurysm, 3-4 cm diameter, 3 months
after catheterization as a result of wound
sepsis.
Ancillary procedures
Many laboratory and clinical studies
have been made to try to increase the
selective uptake ofT-MNDP into tumours.
The most encouraging ancillary agent is
prednisone, which appears to increase the
alkaline phosphatase on the tumour cell
surface in some cases; the effects on normal
cells must be studied further. The possi-
bilities of the use of phenobarbitone as an
enzyme inducer should also be con-
sidered. Fasting appears to be of prac-
tical value (White, 1973). In in vitro
experiments with Ehrlich ascites tumour
cells it had been found that lack ofglucose
in the medium increased the dephos-
phorylation of MNDP but not of ATP
(Fisher, 1968, personal communication;
see Mitchell, 1971a, p. 46). This finding
may explain the striking response,
Inc.R.(b) in a patient (No. 103) with
recurrent multiple metastases of malig-
nant melanoma who also had diabetes,
controlled on tolbutamide. The use of
potassium citrate mixture to try to
reduce the acidosis in tumours did not
appear to be effective. Hyperbaric oxy-
gen seemed to have some effect but it is
doubtful whether this procedure is of
sufficient practical value to justify its
further study. Acetylcholine did not
increase the uptake, as studied by scanning
with 6-1311-iodo-MNDP but produced
local pain in the region of the tumour. It
must be noted that tolazoline (Priscol)
was used as a vasodilator with many ofthe
intra-arterial injections. Recently, inter-
esting results have been obtained by the
use of chloroquine as a DNA repair
inhibitor to try to increase the effects of
the radiation delivered by the radioactive
drug, perhaps selectively in the tumour
cells (Mitchell, 1973).
We have made many attempts to
select patients for treatment on the basis
of measurements of the uptake of MNDP
into the tumour, using the following
investigations:
(i) Measurements of the specific
activity of tritium in samples of
tumour and normal tissue if pos-
sible. (It may be noted that a
value of the DAR of 14 was found
for a biopsy specimen of recurrent
melanoma of the skin taken 35 miii
after intravenous injection of 0 5 Ci
of TRK 397, but there was no
clinical response to treatment.)
(ii) Autoradiographic studies on sec-
tions fronm operation and biopsy
specimens in conjunction with
measurements of the specific
activity.
(iii) Autoradiographic studies of in vitro
uptake by primary cultures of
malignant cells freshly grown from
specimens of tumour or ascitic
fluid. Many of the cases for which
the cells in culture showed uptake
had been treated with prednisone.386 J. S. MITCHELL
(iv) Radioisotope scanning using the
radioiodine labelled derivative,
6 - 1311 - iodo - 2 - methyl - 1,4 -
naphthaquinol - bis(di - ammonium
phosphate), abbreviated 6-1311-
iodo MNDP. (Details of this work
will be published elsewhere.) See
Marrian et (al. (I 969).
CONCL-USIONS
The results of the trials of T-MNDP
as a radioactive drug in the treatment of
selected patients with advanced malignant
diseases of various types and sites are in
general modest. The clinical results in
some patients have been useful. It is
likely that no responses can be expected
for certain types and sites of tumour,
e.g., inoperable carcinoma of the stomach
for treatment by intravenous injections,
inoperable cerebral glioma for treatment
by intra-arterial injections. It is con-
cluded that much further investigation is
desirable.
It is suggested that Phase III should
be started, with controlled clinical trials,
with proper design and random alloca-
tion of patients-perhaps with chemo-
therapy in the control groups for the
treatment ofinoperable cases ofcarcinoma
of the colon and of carcinoma of the
pancreas.
Further studies of ancillary agents and
procedures to improve the selection of
patients appear to be necessary.
The possibilities of T-MNDP in the
treatment of selected patients with
advanced carcinoma of the rectum, breast
and ovary and with advanced Hodgkin's
disease and testicular seminoma have
probably not been fully explored and
appear to justify further investigation.
Studies of rare tumours, such as primary
hepatoma, should also be envisaged.
This work provides further evidence
that tritium, when incorporated into a
suitable compound, can produce thera-
peutic effects in patients with malignant
diseases of certain sites and types. The
scope and limitations of the effectiveness
of T-MNDP as a radioactive drug appear
to depend not only on the nature and
properties of the carrier molecule, which
are obviously of essential importance, but
also on the biochemistry and patho-
logical physiology ofthe tumour, especially
on the blood supply and size ofthe tumour
masses and the interrelationships of the
tumour and the host.
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